Physician profile
Manuel J Datiles
NPI 1043577000
$1,092.46
in general payments reported to CMS, 2019-2025
18 companies · $287 in 2025
The $287 reported for 2025 was more than what 84% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $33.25 · 2020: $41.54 · 2021: $160 · 2022: $171 · 2023: $231 · 2024: $169 · 2025: $287.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $687.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $686.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $258.60 | 2022-2025 | Azstarys |
| Cranial Technologies, INC | $226.64 | 2020-2024 | Doc Band |
| Ironshore Pharmaceuticals INC. | $78.48 | 2023 | Jornay Pm |
| Supernus Pharmaceuticals, INC. | $63.46 | 2025 | Qelbree |
| Merck Sharp & Dohme LLC | $62.92 | 2025 | Gardasil 9, Capvaxive, Vaxneuvance |
| Pfizer INC. | $57.92 | 2024-2025 | |
| Welch Allyn | $53.45 | 2021 | |
| Alk-Abello, INC | $52.88 | 2024-2025 | Neffy, Odactra, Ragwitek |
| Sanofi Pasteur INC. | $37.90 | 2019-2024 | |
| Novo Nordisk INC | $35.63 | 2023-2024 | Wegovy, Rybelsus, Ozempic |
| Genentech USA, INC. | $34.75 | 2021 | |
| Glaxosmithkline, LLC. | $34.48 | 2019-2022 | |
| Exact Sciences Corporation | $20.14 | 2023 | Cologuard Collection Kit |
| Cumberland Pharmaceuticals, INC. | $17.71 | 2024 | Kristalose |
| Abbvie INC. | $15.61 | 2024 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Adlon Therapeutics L.P. | $14.45 | 2021 | |
| Tris Pharma INC | $14.08 | 2023 | Dyanavel Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $13.36 | 2024 | Trintellix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manuel Datiles listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.